UCB announces U.S. FDA acceptance of new drug application an

New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine...

Related Keywords

United Kingdom , China , Japan , Denmark , Brussels , Bruxelles Capitale , Belgium , Great Britain , Daphne Teo , Charl Van Zyl , Jim Baxter , Iris Loew Friedrich , Neuromuscul Disord , Antje Witte , Laurent Schots , Us Communications , Brand Communications , Eu International , Twitter , European Commission , Drug Administration , Neurology Solutions Head , Corporate Communications , Myasthenia Gravis Foundation Of America , European Medicines Agency , Lancet Reg Health West Pac , Committee For Medicinal Products Human Use , Source Ucb Inc , Drug Administration Accessed , Marketing Authorization Application , New Drug Application , Medicinal Products , Human Use , Executive Vice President Neurology Solutions , International Markets , Myasthenia Gravis Activities , Daily Living , Executive Vice President , Chief Medical Officer , Generalized Myasthenia Gravis , Quantitative Myasthenia Gravis , Myasthenia Gravis Composite , Myasthenia Gravis Quality , Rare Diseases , Euronext Brussels , Accessed October , Gravis Foundation , Clinical Overview , Patients With Moderate , Severe Generalized Myasthenia Gravis , Multicenter Clinical , Test Efficacy , Adult Patients With Generalized Myasthenia , Accesed October , Reg Health West Pac , Neurological Disorders , Gravis Fact , Life Outcomes , Accessed August , Medicines Agency , Ucb , Nc ,